Bibliographic Details
| Title: |
The usefulness of Olanzapine plasma concentrations in monitoring treatment efficacy and metabolic disturbances in first-episode psychosis. |
| Authors: |
Arnaiz, J. A. (AUTHOR), Rodrigues-Silva, C. (AUTHOR), Mezquida, G. (AUTHOR), Amoretti, S. (AUTHOR), Cuesta, M. J. (AUTHOR), Fraguas, D. (AUTHOR), Lobo, A. (AUTHOR), González-Pinto, A. (AUTHOR), Díaz-Caneja, M. C. (AUTHOR), Corripio, I. (AUTHOR), Vieta, E. (AUTHOR), Baeza, I. (AUTHOR), Mané, A. (AUTHOR), García-Rizo, C. (AUTHOR), Bioque, M. (AUTHOR), Saiz, J. (AUTHOR), Bernardo, M. (AUTHOR), Mas, S. (AUTHOR), PEPs group (AUTHOR), Torra, Mercè (AUTHOR) |
| Source: |
Psychopharmacology. Mar2021, Vol. 238 Issue 3, p665-676. 12p. 2 Charts, 2 Graphs. |
| Subjects: |
Metabolic disorders, Drug monitoring, Treatment effectiveness, Smoking, Valproic acid, Olanzapine |
| Abstract: |
Introduction: The role of Olanzapine therapeutic drug monitoring is controversial. The present study explores the associations of Olanzapine plasma concentrations with clinical response and metabolic side effects in first episode psychosis (FEP) after 2 months of treatment. Methods: Forty-seven patients were included. Improvement in clinical symptomatology was assessed using the PANSS. Metabolic assessment included weight, blood pressure, waist circumference, blood glucose, total cholesterol, high-density lipoprotein, low-density lipoprotein, and triglycerides. Results: The Olanzapine plasma concentrations after 2 months of treatment were positively correlated with weight gain (r = 0.49, p = 0.003), and a concentration > 23.28 ng/mL was identified as a positive predictor of weight gain (≥ 7%). The Olanzapine concentration to dose (C/D) ratio was positively correlated with the percentage of improvement in the total PANSS (r = 0.46, p = 0.004), and a C/D ratio > 2.12 was identified as a positive predictor of a good response (percentage of improvement > 30%) after 2 months of treatment. We also identified several factors that could alter Olanzapine pharmacokinetics: gender (p = 0.03), diagnosis (p = 0.05), smoking habit (p = 0.05), and co-medications such as valproic acid (p = 0.05) and anxiolytics (p = 0.01). Discussion: In conclusion, our results suggest that therapeutic drug monitoring of Olanzapine could be helpful to evaluate therapeutic efficacy and metabolic dysfunction in FEP patients treated with Olanzapine. [ABSTRACT FROM AUTHOR] |
|
Copyright of Psychopharmacology is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Psychology and Behavioral Sciences Collection |
